Tumor-feeding artery diameter reduction is associated with improved short-term effect of hepatic arterial infusion chemotherapy plus lenvatinib treatment

Table 3 Univariate and multivariate logistic regression analysis for efficacy of treatment with hepatic arterial infusion chemotherapy plus lenvatinib

	1 mo			3 mo			6 mo
	Univariate	Multivariate		Univariate	Multivariate		Univariate	Multivariate
	P1 value	P2 value	OR (95%CI)	P1 value	P2 value	OR (95%CI)	P1 value	P2 value	OR (95%CI)
TFA (reduced/basically unchanged)	< 0.001	0.001	0.12 (0.03-0.43)	< 0.001	0.001	0.06 (0.01-0.29)	0.002	0.002	0.14 (0.04-0.47)
Sex (male/female)	0.680	-	-	0.349	-	-	0.892	-	-
Age (≤ 60/> 60)	0.850	-	-	0.868	-	-	0.573	-	-
ECOG (0/1)	0.412	-	-	0.147	-	-	0.365	-	-
HBsAg (positive/negative)	0.122	-	-	0.113	-	-	0.784	-	-
AFP, ng/mL (≤ 400/> 400)	0.003	0.018	0.17 (0.04-0.73)	0.089	0.546	-	0.040	0.122	-
Child-Pugh (A/B)	0.384	-	-	0.897	-	-	0.869	-	-
Tumor size, cm (≤ 10/> 10)	0.166	-	-	0.053	0.021	7.65 (1.36-42.88)	0.625	-	-
Tumor number (≤ 3/> 3)	0.609	-	-	0.533	-	-	0.280	-	-
PVTT (absent/present)	0.220	-	-	0.169	-	-	0.577	-	-
HVTT (absent/present)	0.842	-	-	0.455	-	-	1.000	-	-
Metastasis (absent/present)	0.960	-	-	0.694	-	-	0.615	-	-

Any factors that were statistically significant at P < 0.10 in the univariate logistic regression analysis were candidates for entry into the multivariate logistic regression analysis. TFA: The tumor-feeding artery; ECOG PS: Eastern Cooperative Oncology Group performance status; HBsAg: Hepatitis B surface antigen; AFP: Alfa-fetoprotein; PVTT: Portal vein tumor thrombus; HVTT: Hepatic vein tumor thrombus; OR: Odds ratio; CI: Confidence interval.